One ‐year clinical experience on the use of Nintedanib in systemic sclerosis

We reviewed eleven patients with Systemic Sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and who started Nintedanib. AbstractWe reviewed 11 patients with systemic sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non-specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5  mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated.
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: CASE SERIES Source Type: research